Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288884 | 0.79 | ADRA2A (0.52) | LMNAKMT2ADRD2DRD4DRD3 | |
| SCHEMBL4285897 | 0.79 | KMO (0.51) | KMT2AMAPK1HSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL1581980 | 0.78 | MTNR1A (0.51) | LMNAKMT2AMTNR1AMTNR1BCDK4 | |
| Hydrochloric Acid SCHEMBL4292429 | 0.77 | LMNA (0.43) | LMNAKMT2AMTNR1AMTNR1BCDK4 | |
| Hydrochloric Acid SCHEMBL4293143 | 0.77 | LMNA (0.43) | LMNAKMT2AMTNR1AMTNR1BCDK4 | |
| SCHEMBL4292117 | 0.76 | ESR1 (0.52) | — | |
| SCHEMBL4281619 | 0.76 | STAT3 (0.51) | KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL4552154 | 0.76 | STAT3 (0.51) | KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL4283648 | 0.75 | LMNA (0.43) | LMNAKMT2ATP53TSHRSMN1; SMN2 | |
| SCHEMBL4292497 | 0.75 | KMO (0.49) | KMT2AMAPK1HSD17B10TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885KMT2A 1049/4885MTNR1A 1411/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885KMT2A 1049/4885MTNR1A 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.